Across TCGA pan-cancer cohorts, LINC02382 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LINC02382’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC02382 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC02382 is over-expressed in tumor, although a few such as BRCA and LUAD show the opposite, repressed pattern.
BRCA, HNSC, and LUAD are the cancer types where LINC02382 tumor–normal differential expression is most reproducible.